Related Experiment Video
Updated: May 14, 2025
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Cardiovascular Medication and Health Service Use in Individuals With Cancer: A Retrospective Population-Based Cohort
Jin Quan Eugene Tan1,2, Huah Shin Ng1,2, Richard Woodman1
1Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Background:
Cancer and cardiovascular disease (CVD) frequently coexist, but little is known about CVD medication use in cancer survivors. The aim of this study was to compare CVD medication and medical service use between individuals with and without cancer.
Methods:
Retrospective cohort study linking Australian National Health Survey 2020-2021 data from participants aged ≥ 25 years to medication dispensing, medical services, and death registry data via the Multi-Agency Data Integration Project. Logistic regression was used to compare patterns of CVD medication use between cancer and non-cancer groups and negative binomial regression to examine patterns of medical service utilisation by cancer and CVD status.
Results:
The analysis included 1828 individuals with a history of cancer (cancer survivors) and 7505 people without cancer. Although cancer survivors had a higher prevalence of CVD (31% vs. 13%) compared to people without cancer, there was no difference in the adjusted use of CVD medications (adjusted odds ratios: 1.15; 95% CI = 1.00-1.33) between these two groups. There was, however, an increased rate of health service use in those with cancer alone (adjusted rate ratios (aRR): 1.39; 95% CI = 1.29-1.50), those with CVD alone (aRR: 1.71; 95% CI = 1.63-1.80), and those with both conditions (aRR: 2.10; 95% CI = 1.97-2.25) compared to people without cancer or CVD.
Conclusions:
Despite having a higher prevalence of CVD and higher health service utilisation, the overall use of CVD medication did not differ between people with and without cancer. Cancer survivors with CVD had a higher rate of medical services use compared with persons with either condition alone or neither condition. Further research should explore the underlying reasons behind these data to inform strategies to mitigate the detrimental effects of comorbid CVD in cancer.
Related Concept Videos
01:23Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
01:21Cancer Survival Analysis
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
02:59Cancer Prevention
Some...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...